Plasma exchange as a treatment for endogenous glycosaminoglycan anticoagulant induced haemorrhage in a patient with myeloma kidney.
A 57-year-old man with end-stage renal failure secondary to myeloma kidney developed haemorrhagic complications due to endogenous glycosaminoglycan anticoagulant production. Glycosaminoglycan levels and anticoagulant effect were reduced by plasma exchange and this contributed to control of the haemorrhagic manifestations.
Goddard
I R
IR
Department of Medicine, University of Dundee, Ninewells Hospital, UK.
Stewart
W K
WK
Hodson
B A
BA
Dawes
J
J
D001777:Blood Coagulation; D001780:Blood Coagulation Tests; D004381:Duodenal Ulcer / Q000150:complications; D006025:Glycosaminoglycans / Q000097:blood*; D006801:Humans; D007146:Immunoglobulin lambda-Chains; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000150:complications*; D010438:Peptic Ulcer Hemorrhage / Q000209:etiology / Q000628:therapy*; D010951:Plasma Exchange
D006025:Glycosaminoglycans; D007146:Immunoglobulin lambda-Chains